Published Date: 02 Mar 2023
Multiple sclerosis patients who cut calories two days a week not only lost weight but also experienced better cognition and other benefits in a new study.
Read Full NewsThe U.S. Food and Drug Administration has declined to approve Achieve Life Sciences' drug to treat nicotine dependence in adults, citing unresolved issues found at a...
The profession has always attracted perfectionists. Experts worry a more fear-based version of the trait could affect both doctors and patients.
Rucaparib maintenance delays both first and second subsequent therapies among patients with advanced ovarian cancer.
1.
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma
2.
Study finds 81% of cancer cures touted by TikTok videos are fake
3.
The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.
4.
Inside the Major Findings From the NHS-Galleri Trial
5.
What is Mohs micrographic surgery? 8 FAQs about Mohs
1.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
2.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
3.
From Muscle Soreness to Improved Endurance: The Benefits of Monitoring Lactic Acid Levels
4.
The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies
5.
The Role of Alanine Aminotransferase in Liver Health and Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation